Mitochondrial trifunctional protein deficiency
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (January 2008) |
| Mitochondrial trifunctional protein deficiency Classification and external resources |
|
| ICD-9 | 272.8 |
|---|---|
| OMIM | 609015 |
| DiseasesDB | 34111 |
| eMedicine | ped/1284 |
Mitochondrial trifunctional protein deficiency is an autosomal recessive fatty acid oxidation disorder[1] that prevents the body from converting certain fats to energy, particularly during periods without food . People with this disorder have inadequate levels of an enzyme that breaks down a certain group of fats called long-chain fatty acids.
Contents |
[edit] Diagnosis
Onset of this disorder may begin during infancy or later in life. Signs and symptoms of the early onset form can include feeding difficulties, lack of energy (lethargy), low blood sugar (hypoglycemia), muscle weakness (hypotonia), liver problems, and a high risk for complications such as life-threatening heart and breathing problems, coma, and sudden unexpected death. The late-onset form is usually less severe; signs and symptoms can include hypotonia, muscle pain, a breakdown of muscle tissue, and abnormalities in the nervous system that affect arms and legs (peripheral neuropathy). Episodes of mitochondrial trifunctional protein deficiency can be triggered by periods of fasting or by illnesses such as viral infections. Diagnosis of this disorder is often confirmed using tandem mass spectrometry.[1]
[edit] Genetics
Mutations in the HADHA or HADHB genes can lead to inadequate levels of an enzyme complex known as mitochondrial trifunctional protein. Long-chain fatty acids from food and body fat cannot be metabolized and processed without sufficient levels of this enzyme complex. As a result, these fatty acids are not converted to energy, which can lead to characteristic features of this disorder, such as lethargy and hypoglycemia. Long-chain fatty acids or partially metabolized fatty acids may build up in tissues and damage the liver, heart, and muscles, causing more serious complications.
[edit] See also
This article incorporates public domain text from The U.S. National Library of Medicine
[edit] External links
- Overview of condition at NLM Genetics Home Reference
[edit] References
- ^ a b Solish JO, Singh RH (2002). "Management of fatty acid oxidation disorders: a survey of current treatment strategies". J Am Diet Assoc. 102 (12): 1800–1803. doi:. PMID 12487544.
|
|||||||||||||||||||||||
 |
This genetic disorder article is a stub. You can help Wikipedia by expanding it. |
